1977
DOI: 10.1016/s0140-6736(77)90725-5
|View full text |Cite
|
Sign up to set email alerts
|

Deprenyl in Parkinson's Disease

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
103
2
2

Year Published

1978
1978
1997
1997

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 269 publications
(112 citation statements)
references
References 10 publications
5
103
2
2
Order By: Relevance
“…This suggests that the inhibitor does not further accumulate in the brain after the first few days, presumably reflecting a rapid metabolism to amphetamine and methamphetamine (Reynolds, Elsworth, Blau, Sandler, Lees & Stern, 1978). These results are consistent with those of , who show no clinically significant change in tolerance to tyramine after 18 months treatment and they serve to underline the safety of the drug in clinical practice (Birkmayer et al, 1977;Lees et al, 1977 Received October 8,1979 …”
Section: Moon Hk and Holler Ch (1970supporting
confidence: 74%
“…This suggests that the inhibitor does not further accumulate in the brain after the first few days, presumably reflecting a rapid metabolism to amphetamine and methamphetamine (Reynolds, Elsworth, Blau, Sandler, Lees & Stern, 1978). These results are consistent with those of , who show no clinically significant change in tolerance to tyramine after 18 months treatment and they serve to underline the safety of the drug in clinical practice (Birkmayer et al, 1977;Lees et al, 1977 Received October 8,1979 …”
Section: Moon Hk and Holler Ch (1970supporting
confidence: 74%
“…The beneficial effect of nocturnal dosing with levodopa on morning performance suggests that its hypnotic-like effect is secondary to improvement in control of Parkinson's disease. Lees et al (1977) found that difficulty in turning voluntarily during the night was responsive to dopaminergic therapy. The patient's improved ability to turn in bed may allow a more comfortable position to be adopted.…”
Section: Discussionmentioning
confidence: 99%
“…Thus AGN 1135 potentially could be a useful drug like selegiline (Birkmayer et al, 1977;Lees et al, 1977) for potentiating the anti-Parkinson action of L-DOPA.…”
Section: Discussionmentioning
confidence: 99%